Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press75310.17650/2313-805X-2025-12-1-8-13REVIEW ARTICLESОБЗОРНЫЕ СТАТЬИSignaling cascades are targets for breast cancer therapy in the light of genome – wide sequencing dataСигнальные каскады – мишени для терапии рака молочной железы в свете данных полногеномного секвенированияhttps://orcid.org/0000-0002-7693-3777GulyaevaL. F.ГуляеваЛ. Ф.
Russian Federation

 Lyudmila Fyodorovna Gulyaeva 

2/12 Timakova St., Novosibirsk 630060, Russia 

Людмила Федоровна Гуляева  

Россия, 630060 Новосибирск, ул. Тимакова, 2/12

lfgulyaeva@gmail.comhttps://orcid.org/0000-0002-8950-5368FilipenkoM. L.ФилипенкоМ. Л.
Russian Federation

8 Akademika Lavrentieva St., Novosibirsk 630090, Russia 

Россия, 630060 Новосибирск, ул. Академика  Лаврентьева, 8 

https://orcid.org/0000-0002-3898-4127KushlinskiiN. E.КушлинскийН. Е.
Russian Federation

24 Kashirskoe Shosse, Moscow 115522, Russia 

115522 Москва, Каширское шоссе, 24 

Federal Research Center for Fundamental and Translational MedicineФГБНУ «Федеральный исследовательский центр фундаментальной и трансляционной медицины»Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the Russian Academy of SciencesФГБУ «Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук»N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России150120251218131304202513042025Copyright ©; 2025, Gulyaeva L.F., Filipenko M.L., Kushlinskii N.E.Copyright ©; 2025, Гуляева Л.Ф., Филипенко М.Л., Кушлинский Н.Е.2025Gulyaeva L.F., Filipenko M.L., Kushlinskii N.E.Гуляева Л.Ф., Филипенко М.Л., Кушлинский Н.Е.https://creativecommons.org/licenses/by/4.0https://umo.abvpress.ru/jour/article/view/753

Development of next generation sequencing technologies allows to identify a large number of genetic landscape types in various cancers including breast cancer. Frequent genetic abnormalities identified using whole genome sequencing are point mutations (missense, nonsense mutations), deletions, insertions, which usually lead to activation of protooncogenes and inactivation of tumor suppressor genes. Genome sequencing of malignant tumors allowed, on one hand, to identify driver mutations in carcinogenic genes in different organs, and on the other – to use mutated genes for targeted therapy. Study of biological functions of these genes from the point of view of their contribution to carcinogenesis allows to better understand its mechanism. In this review, signaling cascades of breast cancer with identified mutated genes – targets for therapy – are analyzed.

Развитие технологий секвенирования нового поколения позволяет выявлять множество вариантов генетического ландшафта в различных видах рака, в том числе рака молочной железы. Одним из частых генетических повреждений, обнаруживаемых с использованием полногеномного секвенирования, являются точечные мутации (миссенс-, нонсенсмутации), делеции, инсерции, приводящие, как правило, к активации протоонкогенов и инактивации опухолевых супрессоров. Секвенирование генома злокачественных опухолей позволило, с одной стороны, выявить драйверные мутации в генах канцерогенеза того или иного органа, а с другой, использовать мутантные гены как мишени для таргетной терапии. исследование биологических функций таких генов с точки зрения их вклада в канцерогенез помогает лучше понять его механизмы. В данном обзоре проанализированы сигнальные каскады рака молочной железы с выявленными мутантными генами – мишенями для таргетной терапии.

breast cancerDNA sequencingsignaling cascadetargeted therapyрак молочной железыДНк-секвенированиесигнальный каскадтаргетная терапияThe work was carried out within the framework of the budget project of the Federal Research Center for Fundamental and Translational Medicine on the topic “Post-genomic high-tech studies of the mechanisms of development of socially significant diseases and stress-induced conditions”.Работа выполнена в рамках бюджетного проекта ФГБНУ «Федеральный исследовательский центр фундаментальной и трансляционной медицины» по теме «Постгеномные высокотехнологичные исследования механизмов развития социально значимых заболеваний и стресс-индуцированных состояний».Marti J.L.G., Hyder T., Nasrazadani A. et al. The evolving landscape of HER2-directed breast cancer therapy. Curr Treat Options Oncol 2020;21(10):82. DOI: 10.1007/s11864-020-00780-6Tarantino P., Viale G., Press M.F. et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol 2023;34(8):645–59. DOI: 10.1016/j.annonc.2023.05.008Ferguson K.M. Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys 2008;37:353–73. DOI: 10.1146/annurev.biophys.37.032807.125829Li X., Zhao L., Chen C. et al. Can EGFR be a therapeutic target in breast cancer? Biochim Biophys Acta Rev Cancer 2022;1877(5):188789. DOI: 10.1016/j.bbcan.2022.188789Raghav K.P.S., Moasser M.M. Molecular pathways and mechanisms of HER2 in cancer therapy. Clin Cancer Res 2023;29(13):2351–61. DOI: 10.1158/1078-0432.CCR-22-0283Lyu H., Han A., Polsdofer E. et al. Understanding the biology of HER3 receptor as a therapeutic target in human cancer. Acta Pharm Sin B 2018;8(4):503–10. DOI: 10.1016/j.apsb.2018.05.010Kilroy M.K., Park S., Feroz W. et al. HER3 alterations in сancer and potential clinical implications. Cancers (Basel) 2022;14(24):6174. DOI: 10.3390/cancers14246174Papa F., Grinda T., Rassy E. et al. Long road towards effective HER3 targeting in breast cancer. Cancer Treat Rev 2024;129:102786. DOI: 10.1016/j.ctrv.2024.102786Uliano J., Corvaja C., Curigliano G., Tarantino P. Targeting HER3 for cancer treatment: a new horizon for old target. ESMO Open 2023;8(1):100790. DOI: 10.1016/j.esmoop.2023.100790Hoxhaj G., Manning B.D. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer 2020;20(2):74–88. DOI: 10.1038/s41568-019-0216-7Mishra R., Alanazi S., Yuan L. et al. Activating HER3 mutations in breast cancer. Oncotarget 2018;9(45):27773–88. DOI: 10.18632/oncotarget.25576Murugan A.K., Grieco M., Tsuchida N. RAS mutations in human cancers: roles in precision medicine. Semin Cancer Biol 2019;59:23–35. DOI: 10.1016/j.semcancer.2019.06.007Kamian S., Ashoori H., Vahidian F., Davoudi S. The relevance of common K-RAS gene mutations and K-RAS mRNA expression with clinicopathological findings and survival in breast cancer. Asian Pac J Cancer Prev 2023;24(3):909–14. DOI: 10.31557/APJCP.2023.24.3.909Banys-Paluchowski M., Milde-Langosch K., Fehm T. et al. Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients. Breast Cancer Res Treat 2020;179(2):403–14. DOI: 10.1007/s10549-019-05474-8Hossain M.A. Targeting the RAS upstream and downstream signaling pathway for cancer treatment. Eur J Pharmacol 2024;979:176727. DOI: 10.1016/j.ejphar.2024.176727Wang L., Lu Q., Jiang K. et al. BRAF V600E mutation in triplenegative breast cancer: a case report and literature review. Oncol Res Treat 2022;45(1–2):54–61. DOI: 10.1159/000520453Khojasteh Poor F., Keivan M., Ramazii M. et al. Mini review: the FDA-approved prescription drugs that target the MAPK signaling pathway in women with breast cancer. Breast Dis 2021;40(2):51–62. DOI: 10.3233/BD-201063Miricescu D., Totan A., Stanescu-Spinu I.I. et al. PI3K/AKT/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects. Int J Mol Sci 2020;22(1):173. DOI: 10.3390/ijms22010173Hinz N., Jücker M. Distinct functions of AKT isoforms in breast cancer: a comprehensive review. Cell Commun Signal 2019;17(1):154. DOI: 10.1186/s12964-019-0450-3Nunnery S.Е., Mayer I.A. Targeting the PI3K/AKT/mTOR pathway in hormone-positive breast cancer. Drugs 2020;80(16):1685–97. DOI: 10.1007/s40265-020-01394-wShen L.S., Jin X.Y., Wang X.M. et al. Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Chin Med J 2020;133:1099–108. DOI: 10.1097/CM9.0000000000000745Mosele F., Stefanovska B., Lusque A. et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol 2020;31(3):377–86. DOI: 10.1016/j.annonc.2019.11.006Ertay A., Liu H., Liu D. et al. WDHD1 is essential for the survival of PTEN-inactive triple-negative breast cancer. Cell Death Dis 2020;11(11):1001. DOI: 10.1038/s41419-020-03210-5Hanker A.B., Sudhan D.R., Arteaga C.L. Overcoming endocrine resistance in breast cancer. Cancer Cell 2020;37(4):496–513. DOI: 10.1016/j.ccell.2020.03.009Endicott S.J., Ziemba Z.J., Beckmann L.J. et al. Inhibition of class I PI3K enhances chaperone-mediated autophagy. J Cell Biol 2020;219(12):202001031. DOI: 10.1083/jcb.202001031Rugo H.S., Raskina K., Schrock A.B. et al. Biology and targetability of the extended spectrum of PIK3CA mutations detected in breast carcinoma. Clin Cancer Res 2023;29(6):1056–67. DOI: 10.1158/1078-0432.CCR-22-2115Riobo-Del Galdo N.A., Montero Á.L, Wertheimer E.V. Role of Hedgehog signaling in breast cancer: pathogenesis and therapeutics. Cells 2019;8(4):375. DOI: 10.3390/cells8040375Habib J.G., O’Shaughnessy J.A. The hedgehog pathway in triple-negative breast cancer. Cancer Med 2016;5(10):2989–3006. DOI: 10.1002/cam4.833Patel D.K., Kesharwani R., Verma A. et al. Scope of Wnt signaling in the precise diagnosis and treatment of breast cancer. Drug Discov Today 2023;28(7):103597. DOI: 10.1016/j.drudis.2023.103597Xu X., Zhang M., Xu F., Jiang S. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. Mol Cancer 2020;19(1):165. DOI: 10.1186/s12943-020-01276-5Harbeck N., Penault-Llorca F., Cortes J. et al. Breast cancer. Nat Rev Dis Primers 2019;5(1):66. DOI: 10.1038/s41572-019-0111-2Theodosiou A., Arhondakis S., Baumann M., Kossida S. Evolutionary scenarios of Notch proteins. Mol Biol Evol 2009;26(7):1631–40. DOI: 10.1093/molbev/msp075Krishna B.M., Jana S., Singhal J. et al. Notch signaling in breast cancer: from pathway analysis to therapy. Cancer Lett 2019;461:123–31. DOI: 10.1016/j.canlet.2019.07.012Huang P., Chen A., He W. et al. BMP-2 induces EMT and breast cancer stemness through Rb and CD44. Cell Death Discov 2017;3:17039. DOI: 10.1038/cddiscovery.2017.39Nilendu P., Kumar A., Kumar A. et al. Breast cancer stem cells as last soldiers eluding therapeutic burn: a hard nut to crack. Int J Cancer 2018;142(1):7–17. DOI: 10.1002/ijc.30898